臨床泌尿器科70巻2号

2016年02月発行

特集 ここが知りたい! 筋層非浸潤性膀胱癌─エキスパートが答える日常診療の疑問点

〈初発腫瘍に対する治療方針〉

BCGの作用機序

著者： 宮崎淳¹

所属機関： ¹筑波大学医学医療系腎泌尿器外科学分野

ページ範囲：P.160 - P.165

文献概要

質問 : BCGの治療効果には，菌株や年齢，性差は関係しますか？

▶ポイント

・BCGの作用メカニズムについて，膀胱癌細胞内にBCGが侵入することが必須．

・BCGが侵入すると，抗原提示細胞への抗原提示が開始される．

・膀胱癌細胞株においても，MHC class IIの発現増強やBCG特異的なCD4＋リンパ球への抗原提示が起き，膀胱癌細胞そのものが，抗原提示に関与していることが示唆される．

参考文献

1） Coley WB : The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 262 : 3─11, 1991

2） Nauts HC and McLaren JR : Coley toxins─the first century. Adv Exp Med Biol 267 : 483─500, 1990

3） Sharma P, Old LJ and Allison JP : Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncology 34 : 165─172, 2007

4） Morales A, Eidinger D and Bruce AW : Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 : 180─183, 1976

5） Lamm DL, Thor DE, Harris SC, et al : Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124 : 38─40, 1980

6） Behr MA, Wilson MA, Gill WP, et al : Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 : 1520─1523, 1999

7） Brosch R, Gordon SV, Garnier T, et al : Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104 : 5596─5601, 2007

8） Hayashi D, Takii T, Fujiwara N, et al : Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin（BCG）substrains. FEMS Immunol Med Microbiol 56 : 116─128, 2009

9） Secanella-Fandos S, Luquin M and Julian E : Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guerin substrains. J Urol 189 : 711─718, 2013

10） Naka T, Maeda S, Niki M, et al : Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain. J Biol Chem 286 : 44153─44161, 2011

11） Rentsch CA, Birkhauser FD, Biot C, et al : Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66 : 677─688, 2014

12） Sengiku A, Ito M, Miyazaki Y, et al : A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 190 : 50─54, 2013

13） Redelman-Sidi G, Glickman MS and Bochner BH : The mechanism of action of BCG therapy for bladder cancer─a current perspective. Nat Rev Urol 11 : 153─162, 2014

14） Alexandroff AB, Jackson AM, O’Donnell MA, et al : BCG immunotherapy of bladder cancer : 20 years on. Lancet 353 : 1689─1694, 1999

15） Ratliff TL, Palmer JO, McGarr JA, et al : Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors : initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47 : 1762─1766, 1987

16） Coplen DE, Brown EJ, McGarr J, et al : Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24. J Urol 145 : 1312─1315, 1991

17） Kavoussi LR, Brown EJ, Ritchey JK, et al : Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85 : 62─67, 1990

18） Redelman-Sidi G, Iyer G, Solit DB, et al : Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res 73 : 1156─1167, 2013

19） Ikeda N, Toida I, Iwasaki A, et al : Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin（BCG） : A role of BCG internalization into tumor cells. Int J Urol 9 : 29─35, 2002

20） Lattime EC, Gomella LG and McCue PA : Murine bladder carcinoma cells present antigen to BCG-specific CD4＋T-cells. Cancer Res 52 : 4286─4290, 1992

21） Esuvaranathan K, Alexandroff AB, McIntyre M, et al : Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 154 : 572─575, 1995

22） Zhang Y, Khoo HE and Esuvaranathan K : Effects of bacillus Calmette-Guerin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 161 : 977─983, 1999

23） de Reijke TM, Vos PC, de Boer EC, et al : Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin（BCG）. Urol Res 21 : 349─352, 1993

24） Luo Y, Chen X and O’Donnell MA : Mycobacterium bovis bacillus Calmette-Guerin（BCG）induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 147 : 370─378, 2007

25） Chen F, Zhang G, Iwamoto Y, et al : BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol 12 : 5─8, 2005

26） Pook SH, Rahmat JN, Esuvaranathan K, et al : Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic. Oncol Rep 18 : 1315─1320, 2007

27） See WA, Zhang G, Chen F, et al : Bacille-Calmette Guerin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1. BJU Int 103 : 1714─1720, 2009

28） Sandes E, Lodillinsky C, Cwirenbaum R, et al : Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines. Int J Mol Med 20 : 823─828, 2007

29） Herr HW : Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urol 70 : 65─68, 2007

30） Joudi FN, Smith BJ, O’Donnell MA, et al : The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 : 1634─1639, 2006

31） Heiner JG and Terris MK : Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol 26 : 137─140, 2008

32） Palou J, Sylvester RJ, Faba OR, et al : Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 62 : 118─125, 2012

33） Kluth LA, Fajkovic H, Xylinas E, et al : Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 31 : 1029─1036, 2013